Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EVT 302 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | EVT 302, 5 mg once Daily |
| 2 | PLACEBO_COMPARATOR | Placebo once daily |
| 3 | EXPERIMENTAL | EVT 302 plus open label Nicotine replacement |
| 4 | ACTIVE_COMPARATOR | Placebo plus nicotine replacement therapy |
| Name | Type | Description |
|---|---|---|
| EVT 302 | DRUG | EVT 302 5 mg once daily |
| Placebo | DRUG | Placebo to match EVT 302, 5 mg |
| EVT 302 plus open label Nicotine replacement | DRUG | Double-blind EVT 302 plus open label nicotine replacement |
| Placebo plus open label Nicotine Replacement | DRUG | Double-blind placebo plus open label Nicotine replacement patch 21 mg once daily. |
| EVT 302, 10 mg | DRUG | 2 X EVT 302, 5 mg tablets |
| Nicotine replacement therapy (NRT) | DRUG | NRT patch containing 21 mg of nicotine |
| NRT placebo | DEVICE | Medically inert plaster cut to match the NRT plaster |
Inclusion Criteria: * Smoker of at least 10 cigarettes daily * Motivated to quit smoking * Reports at least one unsuccessful attempt to quit in the last 2 years * In generally good health * Provides written informed consent to participate in the sudy Exclusion Criteria: * Pregnant or nursing fema...
EVT 302 is an investigational small molecule being developed for smoking cessation. It is in Phase 2 clinical development and has been studied in two completed trials in Germany, with a total enrollment of 490 participants.
EVT 302 is being developed by Evotec SE, a company listed on the stock exchange under the ticker EVO. The drug is currently in Phase 2 clinical trials for smoking cessation.
EVT 302 is in Phase 2 clinical development. It has completed two Phase 2 trials, and it is not yet approved by regulatory authorities. The drug remains investigational and is being studied for smoking cessation.
EVT 302 has been studied in two completed Phase 2 trials. NCT00622752 evaluated its effects with or without nicotine replacement therapy on craving and withdrawal in healthy male smokers, enrolling 90 participants. NCT00738595 assessed its effectiveness in smoking cessation, enrolling 400 participants. Both trials were conducted in Germany.
EVT 302 is the only name provided for this drug in the available data. No alternative names have been reported, so it is not known to be the same as any other marketed or investigational drug.